Esflurbiprofen
As of the edition of 20 October 2026, Esflurbiprofen is a small molecule: marketed, first approved in 2015 (JP); acts on PTGS1 and PTGS2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Small molecule
- Brand name
- Loqoa
- First approved
- 28 September 2015 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Taisho Pharmaceutical
- Registered trials
- 1, 0 stopped early
- Disease areas
- Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Taisho Pharmaceutical | Applicant and Lead sponsor of trials | 2015 to now |